Doravirine/islatravir (Idvynso) vs Emtricitabine (Emtriva)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV reverse transcriptase · full HIV pipeline
Doravirine/islatravir (Idvynso)
Marketed by Merck & Co.
NCT05631093 · Phase 3 · active, not recruiting
Trial 051 randomized 551 virologically suppressed adults with HIV-1 2:1, open-label, to switch to once-daily doravirine/islatravir or stay on their baseline antiretroviral regimen. The primary efficacy endpoint was the proportion with HIV-1 RNA at or above 50 copies/mL at Week 48, tested for non-inferiority with a 4-percentage-point margin. The rate was 1.4% after the switch and 4.9% on baseline therapy (difference -3.58, 95% CI -7.81 to -0.77), so non-inferiority was shown and the primary endpoint was met. The other registered primaries are adverse-event rates. Source: ClinicalTrials.gov posted results and the IDVYNSO US label, section 14.
Next expected readout: May 2029 · NCT04776252 (registry estimate)
Reported efficacy
Percentage of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) ≥50 Copies/mL at Week 48; Percentage of Participants Who Experience Adverse Events (AEs) Through Week 48; Percentage of Participants Who Discontinue Study Intervention Due to AEs Through Week 48: HIV-1 RNA at or above 50 copies/mL at Week 48 (FDA Snapshot), switch to doravirine/islatravir (n=342) vs staying on bictegravir/emtricitabine/tenofovir alafenamide (n=171): 1.5% vs 0.6%; risk difference 0.88 percentage points (95% CI -1.86 to 2.90), non-inferiority p=0.003 against a 4-point margin (CT.gov posted results). (met)
Result source: NCT05630755
Emtricitabine (Emtriva)
Marketed by Gilead Sciences and partners
NCT00112047 · Phase 3 · completed
The trial randomized 517 participants to an active comparator, but treatment was open-label rather than double-blinded. Its hard clinical virologic endpoint was met: 84.4% versus 72.8% achieved confirmed HIV-1 RNA below 400 copies/mL at week 48 (p=0.002; 95% CI for the difference, 4.3% to 18.6%), supporting non-inferiority and a favorable result, but the lack of blinding limits the evidence strength.
Next expected readout: June 2029 · NCT07792096 (registry estimate)
Reported efficacy
Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm (48 weeks): Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm (48 weeks): EFV+FTC+TDF 84.4 Percentage of participants | CBV+EFV 72.8 Percentage of participants (met)
Result source: NCT00112047
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Doravirine/islatravir (Idvynso) | Emtricitabine (Emtriva) |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | —Trial running · NCT05630755 | —Not posted · NCT00002416 |
| HIV-1 RNA 50 copies/mL or more (week 48) | —Trial running · NCT05630755 | —Not posted · NCT00002416 |
| CD4 count, change (week 48) | —Trial running · NCT05630755 | —Not posted · NCT00002416 |
HIV-1 RNA below 50 copies/mL (week 48)
- Doravirine/islatravir (Idvynso)
- —Trial running · NCT05630755
- Emtricitabine (Emtriva)
- —Not posted · NCT00002416
HIV-1 RNA 50 copies/mL or more (week 48)
- Doravirine/islatravir (Idvynso)
- —Trial running · NCT05630755
- Emtricitabine (Emtriva)
- —Not posted · NCT00002416
CD4 count, change (week 48)
- Doravirine/islatravir (Idvynso)
- —Trial running · NCT05630755
- Emtricitabine (Emtriva)
- —Not posted · NCT00002416
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Doravirine/islatravir (Idvynso)'s landscape · Emtricitabine (Emtriva)'s landscape